Related Experiment Video
Updated: Feb 7, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants
Natalia V Mitiushkina1, Vladislav I Tiurin1, Aglaya G Iyevleva2
1N.N. Petrov Institute of Oncology, St.-Petersburg, Pesochny, Leningradskaya 68, 197758, Russia.
Abstract:
Multiple laboratory evidences indicate that distinct variants of ALK translocations differ in their biochemical properties and responsiveness to ALK tyrosine kinase inhibitors (TKIs). These data are supported by some clinical studies, which showed improved responses to crizotinib in non-small cell lung cancer (NSCLC) patients carrying particular variants of ALK translocation. We retrospectively considered 64 Russian patients with ALK-rearranged NSCLC, who were treated by crizotinib (n = 23), ceritinib (n = 39) or alectinib (n = 2). ALK fusion variants were genotyped by PCR. Median progression-free survival (PFS) approached to 18 and 21 months in subjects with "short" (v.3a/b, v.5a/b) vs. "long" (TAPE-domain containing) fusion variants (p = 0.783), respectively; similar data were obtained while comparing EML4/ALK variant 1 vs. other ALK translocations (19 and 21 months, respectively; p = 0.604). Objective response rates were also strikingly similar in the above groups ("short": 88%, "long": 77%, p = 0.479; variant 1: 76%, other translocations: 81%, p = 0.753). Furthermore, ALK variants did not influence the disease outcomes when patients treated by crizotinib and ceritinib were analyzed separately. Overall, PFS on ALK TKI did not depend on whether the drug was administered upfront or after chemotherapy. Ceritinib produced significantly longer PFS than crizotinib (p = 0.022). In conclusion, this study revealed that distinct ALK translocation variants render similar clinical responsiveness to ALK inhibitors.
Insights
Distinct anaplastic lymphoma kinase (ALK) fusion variants in non-small cell lung cancer (NSCLC) show similar responses to ALK tyrosine kinase inhibitors (TKIs). This suggests variant type does not impact treatment effectiveness for ALK-rearranged NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Anaplastic lymphoma kinase (ALK) translocations are key drivers in a subset of non-small cell lung cancer (NSCLC).
- Preclinical data suggest varying biochemical properties and inhibitor responsiveness among different ALK fusion variants.
- Clinical evidence is emerging regarding differential responses to ALK tyrosine kinase inhibitors (TKIs) based on specific ALK variants.
Purpose of the Study:
- To investigate the clinical impact of distinct anaplastic lymphoma kinase (ALK) translocation variants on treatment outcomes in patients with ALK-rearranged non-small cell lung cancer (NSCLC).
- To compare the efficacy of crizotinib, ceritinib, and alectinib across different ALK fusion variants.
Main Methods:
- Retrospective analysis of 64 Russian patients with ALK-rearranged NSCLC treated with crizotinib, ceritinib, or alectinib.
- Genotyping of ALK fusion variants using polymerase chain reaction (PCR).
- Comparison of progression-free survival (PFS) and objective response rates (ORR) between different ALK variant groups.
Main Results:
- No significant differences in median PFS or ORR were observed between patients with 'short' (v.3a/b, v.5a/b) versus 'long' (TAPE-domain containing) ALK fusion variants.
- Similarly, EML4/ALK variant 1 showed comparable outcomes to other ALK translocations regarding PFS and ORR.
- ALK variants did not influence outcomes when analyzed separately for crizotinib and ceritinib treatments.
- Ceritinib demonstrated significantly longer PFS compared to crizotinib (p=0.022).
Conclusions:
- Distinct anaplastic lymphoma kinase (ALK) translocation variants exhibit similar clinical responsiveness to ALK tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC).
- Treatment outcomes were not significantly influenced by the specific ALK fusion variant.
- Ceritinib showed superior efficacy over crizotinib in this patient cohort.
More Related Videos
11:31Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
Published on: May 20, 2016
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
Diversity in Cell Signaling Responses
Graded and Abrupt Responses
Some signaling systems generate...
Nuclear Fusion
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
Histone Variants at the Centromere
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Variability: Analysis
The range is a simple measure of variability, indicating the difference between the highest and...
Random Variables
Uppercase letters such as X or Y denote a random variable. Lowercase letters like x or y denote the value of a random variable. If X is a random variable, then X is written in words, and x is given as a number.
For example, let X = the...